浙江医药：公司子公司新码生物已建立完全自主知识产权的非天然氨基酸偶联技术平台

Group 1 - The company Zhejiang Medicine has established a fully independent intellectual property non-natural amino acid coupling technology platform through its subsidiary, Xinma Bio [2] - This platform enables the development of innovative drug molecules in ADC (Antibody-Drug Conjugates) and long-acting protein drugs, with production efficiency bottlenecks having been overcome in the past two years [2] - The sodium battery investment project is classified as a financial investment project, and currently, there are no significant project matters to disclose [2]